NeoStem, Inc. Subsidiary Progenitor Cell Therapy Announces Cell Therapy Manufacturing Collaboration With ATMI
Published: Nov 04, 2013
NEW YORK, Nov. 4, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a collaboration with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.
Help employers find you! Check out all the jobs and post your resume.